- Home
- ARHS vs ELVN Comparison
ARHS vs ELVN Comparison
Compare ARHS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- ELVN
- Stock Information
- Founded
- ARHS 1986
- ELVN 2016
- Country
- ARHS United States
- ELVN United States
- Employees
- ARHS N/A
- ELVN N/A
- Industry
- ARHS Other Specialty Stores
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- ELVN Health Care
- Exchange
- ARHS Nasdaq
- ELVN Nasdaq
- Market Cap
- ARHS 1.3B
- ELVN 1.2B
- IPO Year
- ARHS 2021
- ELVN 2020
- Fundamental
- Price
- ARHS $11.22
- ELVN $17.69
- Analyst Decision
- ARHS Buy
- ELVN Strong Buy
- Analyst Count
- ARHS 14
- ELVN 5
- Target Price
- ARHS $11.58
- ELVN $41.20
- AVG Volume (30 Days)
- ARHS 2.2M
- ELVN 398.4K
- Earning Date
- ARHS 08-07-2025
- ELVN 08-19-2025
- Dividend Yield
- ARHS N/A
- ELVN N/A
- EPS Growth
- ARHS N/A
- ELVN N/A
- EPS
- ARHS 0.50
- ELVN N/A
- Revenue
- ARHS $1,335,951,000.00
- ELVN N/A
- Revenue This Year
- ARHS $7.07
- ELVN N/A
- Revenue Next Year
- ARHS $7.64
- ELVN N/A
- P/E Ratio
- ARHS $22.44
- ELVN N/A
- Revenue Growth
- ARHS 4.76
- ELVN N/A
- 52 Week Low
- ARHS $6.61
- ELVN $13.30
- 52 Week High
- ARHS $13.97
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- ARHS 66.22
- ELVN 34.68
- Support Level
- ARHS $8.40
- ELVN $18.18
- Resistance Level
- ARHS $12.98
- ELVN $20.26
- Average True Range (ATR)
- ARHS 0.63
- ELVN 1.14
- MACD
- ARHS 0.24
- ELVN -0.38
- Stochastic Oscillator
- ARHS 61.57
- ELVN 4.86
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.